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Low rate of bacterial 
co-infection in patients 
with COVID-19
We agree with Michael J Cox and 
colleagues1 that clinical management 
of COVID-19 would be enhanced by 
further characterisation of bacterial 
co-infections. A few case reports 
have described examples of such co-
infections.2,3,4 However, national5 and 
international6 guidelines recommend 
empirical antibiotics for all patients 
who are severely ill with suspected 
COVID-19, and that cessation of 
therapy is left to the clinicians’ 
discretion. Pending the widespread 
avai labi l ity  of  metagenomic 
sequencing as envisaged by Cox and 
colleagues,1 we argue that traditional 
diagnostics still have a role. 
We reviewed all microbiology 
results for patients admitted to 
Whiston hospital (Prescot, UK) with 
PCR-confirmed COVID-19 between 
March 6, 2020, and April 7, 2020. 
Hospital policy for patients admitted 
with community-acquired pneumonia, 
including suspected COVID-19 cases, 
recommends blood cultures and 
pneumococcal and Legionella urinary 
antigen tests based on clinical severity, 
in line with national guidelines.7 We 
collected the data to inform and 
update the hospital’s antimicrobial 
policy, with approval from the Trust 
Quality Improvement and Clinical 
Audit department. We recorded results 
for 7 days from the positive COVID-19 
test because positive samples 
collected after this time period might 
represent hospital-acquired infections. 
Samples unequivocally consistent 
with contamination were considered 
negative.
We identified 195 patients (for 
demographics and microbiology see 
appendix p 1). Five (3% of 195, or 
4% of 137 patients specifically tested), 
had pneumococcal co-infection and 
all survived to hospital discharge. One 
of 31 patients tested was positive for 
the Legionella antigen without lower 
respiratory tract samples to confirm 
legionellosis. Bacteria grew from four 
of 26 sputum samples (appendix 
p 1). All bacteria were Gram-negative 
bacilli more typically associated with 
oropharyngeal colonisation than 
community-acquired pneumonia. 
Our findings suggest that bacterial 
co-infection is uncommon in 
patients with COVID-19 who are 
newly admitted to hospital. The co-
prevalence of pneumococcus and 
severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) was low, 
and Staphylococcus aureus was not 
detected. By contrast, in influenza 
infection the prevalence of bacterial co-
infection in hospitalised patients can 
exceed 30%.8,9 These results suggest 
that routine antibiotics might not be 
indicated in patients with COVID-19. 
If superimposed bacterial community-
acquired pneumonia is suspected, 
coverage for typical pathogens such 
as pneumococcus might suffice, unless 
there is specific clinical concern for 
infection with atypical agents. 
The main strength of our report 
is the correlation of microbiology 
results with all consecutive COVID-19 
admissions. The main limitation is the 
variability of microbiological sampling. 
Our results might not be generalisable 
to other geographical settings. 
Future studies should implement 
s t a n d a r d i s e d  m i c r o b i o l o g i c a l 
sampling for all COVID-19 admissions 
and prospectively correlate the 
prevalence of co-infection with 
mortality rates. Such studies could 
also correlate clinical and laboratory 
findings with the presence of 
co-infection to support rational 
prescribing of antibiotics. 
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